Skip to main navigation
  • About
    • Overview
    • Management
    • Board
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • Press Releases
      • Presentations & Events
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact Us
  • Careers
  • About
    • Overview
    • Management
    • Board
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • Press Releases
      • Presentations & Events
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact Us
  • Careers
Investor Relations

SEC Filing Details

Document Details

Form
8-K
Filing Date
Aug 6, 2024
Document Date
Aug 6, 2024
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
Aligos Therapeutics
Issuer
Aligos Therapeutics, Inc.

Filing Formats

iXBRL
View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
EX-101.DEF - XBRL DEFINITION FILE
EX-101.LAB - XBRL LABEL FILE
EX-101.PRE - XBRL PRESENTATION FILE
XML - XBRL INSTANCE DOCUMENT

Print Page

Email Alerts

RSS

Investor FAQs

US OFFICE 1 Corporate Dr., 2nd Floor South San Francisco, CA 94080

EU OFFICE Gaston Geenslaan 1 / (Building 3) 3001 Leuven, Belgium

CHINA OFFICE Unit 3212, Building A, No. 100, Zunyi Road, Changning District, Shanghai, People’s Republic of China, 200051

Follow Us Linkedin Twitter info@aligos.com

© Aligos Therapeutics 2026

  • Privacy Policy
  • Terms of Service
Menu
  • About
    • Overview
    • Management
    • Board
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Clinical Trials
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • Press Releases
      • Presentations & Events
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact Us
  • Careers